Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, United Kingdom.
Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, United Kingdom.
J Pain Symptom Manage. 2019 Sep;58(3):369-381.e7. doi: 10.1016/j.jpainsymman.2019.06.004. Epub 2019 Jun 13.
Chronic or refractory breathlessness is common and distressing. To evaluate new treatments, outcome measures that capture change in patients' experience are needed.
To explore the extent to which the numerical rating scale (NRS) worst and average, and the Chronic Respiratory Questionnaire capture change in patients' experience during a trial of mirtazapine for refractory breathlessness.
Convergent mixed-methods design embedded within a randomized trial comprising 1) semi-structured qualitative interviews (considered to be the gold standard) and 2) outcome measure data collected pre- and post-intervention. Data were integrated, exploring examples where findings agreed and disagreed. Adults with advanced cancer, chronic obstructive pulmonary disease, interstitial lung disease, or chronic heart failure, with a modified Medical Research Council dyspnea scale grade 3 or 4 were recruited from three U.K. sites.
Data were collected for 22 participants. Eleven had a diagnosis of chronic obstructive pulmonary disease, eight interstitial lung disease, two chronic heart failure, and one cancer. Median age was 71 (56-84) years. Sixteen participants were men. Changes in the qualitative data were commonly captured in the NRS (worst and average) and the Chronic Respiratory Questionnaire. The NRS worst captured change most frequently. Improvement in the emotional domain was associated with physical changes, improved confidence, and control.
This study found that the NRS using the question "How bad has your breathlessness felt at its worst over the past 24 hours?" captured change across multiple domains, and therefore may be an appropriate primary outcome measure in trials in this population. Future work should confirm the construct validity of this question.
慢性或难治性呼吸困难很常见,且令人痛苦。为了评估新的治疗方法,需要能够捕捉患者体验变化的结局指标。
探究数字评定量表(NRS)最差和平均评分,以及慢性呼吸系统问卷(CRQ)在评估米氮平治疗难治性呼吸困难的试验中,在多大程度上可以捕捉患者体验的变化。
采用在随机试验中嵌入的收敛性混合方法设计,包括 1)半结构式定性访谈(被认为是金标准)和 2)干预前后收集的结局测量数据。对数据进行整合,探究了发现一致和不一致的例子。从英国的三个地点招募了患有晚期癌症、慢性阻塞性肺疾病、间质性肺疾病或慢性心力衰竭,改良的医学研究理事会呼吸困难量表等级 3 或 4 的成年人。
共收集了 22 名参与者的数据。11 人患有慢性阻塞性肺疾病,8 人患有间质性肺疾病,2 人患有慢性心力衰竭,1 人患有癌症。中位年龄为 71(56-84)岁。16 名参与者为男性。定性数据的变化通常可以在 NRS(最差和平均)和慢性呼吸系统问卷中捕捉到。NRS 最差评分最常捕捉到变化。情绪域的改善与身体变化、信心和控制的提高有关。
本研究发现,使用“在过去 24 小时内,您的呼吸困难最严重时感觉有多糟糕?”这一问题的 NRS 可以捕捉到多个领域的变化,因此可能是该人群试验中的一个合适的主要结局指标。未来的工作应该确认这个问题的结构效度。